
NICE plans to use broader range of data in guidance
pharmafile | February 5, 2020 | News story | Research and Development | NHS, NHS NICE, NICE
The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.
NICE approved the plan in principle last month. Health Secretary Matt Hancock said that the agency has a duty to ensure their “rules, processes and ways or working” are up to date.
NICE received 130 comments on its process from clinicians, industry and patient groups. It pledged to make sure it rules and processes are up to date to handle new types of medicines.
This new process will involve making the range of data include patient records, real world evidence from health and social care practice outside of trials, such as registries and clinical audits. This should result in improved guidance and allow existing recommendations to be updated more quickly, said the agency.
NICE intends to provide additional details on its plans in a public board meeting next month.
The plans are intended primarily for the development of guidance aimed at health and social care systems. However there is some overlap with its health technology evaluation methods, which are used to review new therapies for use on the NHS.
Conor Kavanagh
Related Content

Scots neonatal innovations target hearing loss and earlier care
Scottish healthcare teams are introducing a range of innovations aimed at improving outcomes for newborns, …

Agentis Health Group acquires Clinical Pharmacist Solutions
Agentis Health Group has acquired Clinical Pharmacist Solutions (CPS), strengthening its pharmacy and digital health …

NICE recommends allergy immunotherapy tablets for younger children
NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …




